Semaglutide Linked to NAION Risk - Summary - MDSpire
From the Journals

Semaglutide Linked to NAION Risk

A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

  • By

  • Andrea Surnit

  • May 11, 2026

  • 3 min

Share

Patients with diabetes treated with semaglutide were found to have a higher long-term risk of nonarteritic anterior ischemic optic neuropathy (NAION) compared to those using other antidiabetic medications, according to a retrospective study analyzing data from approximately 3.35 million diabetes patients. This study, published in JAMA Ophthalmology, controls for variables and includes a significant sample size. Although no short-term risk was identified, a relative risk emerged after two years. Future research is warranted to clarify this association.

Original Source(s)

Semaglutide Linked to NAION Risk

  • by Andrea Surnit

  • May 11, 2026

Related Content

The Smart Contact Lens Evolves

New research shows how microstructured contact lenses can track eye movements with remarkable accuracy using Moiré patterns

  • May 12, 2026

  • 3 min
CSO Meeting 2026 Highlights Convergence of Innovation and Clinical Practice

More than 300 professionals gathered for three days of innovation, education, and collaboration, highlighting the latest advances in ophthalmic technology and clinical practice

  • May 12, 2026

  • 2 min
The Next Frontier in Wet AMD

AI-driven therapy planning is turning OCT from a monitoring tool into a forecasting engine for retina specialists